Fostamatinib disodium: Phase III started

AstraZeneca began 3 double-blind, placebo-controlled, international Phase III trials comprising the OSKIRA program to evaluate 2 regimens of fostamatinib. The start of the program and the transfer of a long-term open-label extension study to AstraZeneca from Rigel trigger 2 milestones payments totaling $25 million to Rigel under a February deal that granted the pharma exclusive, worldwide rights to fostamatinib (see BioCentury, Feb. 22). Rigel remains eligible for about $1.1 billion in milestone payments under the deal. ...